Humacyte, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.humacyte.com

Safety Score

Market Cap $558.46M
Debt $62.12M
Cash $70.92M
EV $549.66M
FCF -$92.26M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$152.87M
EBIT	-$112.49M
ROA	-98%
FCF	-$92.26M
Equity	-$63.72M
Growth Stability	1
PE	-3.65
PB	-8.76
P/FCF	-6.05
Price/Cash	0.13
Debt/Equity	-0.97
Debt/FCF	-0.67
Equity CAGR	30%
Earnings Growth YoY	51%
Earnings Growth QoQ	-31%

Equity CAGR 5Y	30%
Equity CAGR 3Y	-33%
Market Cap	$558.46M
Assets	$114.76M
Total Debt	$62.12M
Cash	$70.92M
Shares Outstanding	115.62M
EV	549.66M
Safety Score	35%
Working Capital	2.06M
Current Ratio	1.1
Shares Growth 3y	4%
Equity Growth QoQ	125%
Equity Growth YoY	-272%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.

SEC Filings

Direct access to Humacyte, Inc. (HUMA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Humacyte, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Humacyte, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Humacyte, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Humacyte, Inc..

Years

Calculation mode

= -$923M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$92M	-$92M	-$92M	-$92M	-$92M	-$92M	-$92M	-$92M	-$92M	-$92M	-$92M	-$923M
DCF		-$84M	-$76M	-$69M	-$63M	-$57M	-$52M	-$47M	-$43M	-$39M	-$36M	-$356M
Value	-$923M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-
ROA	-28%	-41%	-78%	-98%
ROE	-22%	-10%	-818%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.42	-0.51	-0.67
Debt over Equity	0.25	0.26	2.85	-0.97
Growth Stability	-	-	-	1

Good Debt/FCF ratio (-0.67)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.97)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-
Earnings YoY growth	-	-55%	826%	-
Equity YoY growth	-	-4%	-88%	30%
FCF YoY growth	-	-11%	5%	-